Lake Street Maintains Buy on Aquestive Therapeutics, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Lake Street analyst Thomas Flaten maintains a Buy rating on Aquestive Therapeutics (NASDAQ:AQST) and raises the price target from $3 to $8.
March 07, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lake Street analyst Thomas Flaten maintains a Buy rating on Aquestive Therapeutics and raises the price target from $3 to $8.
The increase in price target from $3 to $8 by a reputable analyst suggests a strong bullish outlook on AQST, likely leading to positive investor sentiment and a potential short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100